New immune cells to fight advanced lung cancer

Plain-English translation of NCT07641023 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated August 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This study is testing a new treatment called EB-DuoNK that uses your body's immune cells — specially engineered in a lab to attack cancer — to fight advanced non-small cell lung cancer. The treatment is designed to recognize and destroy cancer cells that have specific markers on their surface. Researchers want to find the right dose and see how well this medication works for people whose cancer has progressed despite standard treatments.

Advanced lung cancer is very difficult to treat, especially when it stops responding to chemotherapy and immunotherapy. This trial exists because doctors need new options for patients in this situation, and early research suggests that engineered immune cells might be able to recognize and destroy cancer cells in ways that current treatments cannot.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced or metastatic non-small cell lung cancer that has grown or spread despite standard treatments like chemotherapy and immunotherapy
your cancer cells have specific protein markers (MSLN, EGFR, and/or HER2) that can be identified through a tumor biopsy or tissue sample
you are in good overall health with an ECOG performance status of 0 or 1 (able to carry out most daily activities)
your organs (blood counts, liver, kidneys) are functioning well enough to tolerate the treatment, as determined by blood tests
you have a life expectancy of at least 12 weeks and are willing to use effective contraception during the study if you can become pregnant

You likely don't qualify if…

you have active, untreated cancer in your brain or spine that is not under control
you have received another type of engineered cell therapy (such as CAR-T cells) within the past 3 months
you have a history of severe reactions to cell therapies, such as severe cytokine release syndrome or neurotoxicity
you have active, uncontrolled infections, including HIV, hepatitis B, or hepatitis C
you are currently pregnant, breastfeeding, or have significant heart disease or serious lung disease that would make the treatment unsafe

What participation looks like

If you qualify, you will first have a biopsy or tissue sample taken to confirm your cancer has the right protein markers. Then you will receive a short course of lymphodepletion (mild chemotherapy to prepare your immune system) followed by an infusion of the engineered immune cells. You will stay in close contact with the research team for follow-up visits and blood tests to monitor how the treatment is working, how you are responding, and any side effects. The study has two phases: an initial phase to find the safest dose, and a second phase to test that dose in more patients.

AI-generated summary from trial data · Aug 14, 2026 · Not medical advice

Trial locations(1 site)

China

Peking University Shenzhen Hospital, Shenzhen, Guangdong